Ariad aims for global oncology play as it files US ponatinib NDA in CML
This article was originally published in Scrip
Executive Summary
Ariad Pharmaceuticals is ahead of schedule with its plans to take on the $4.5 billion chronic myeloid leukaemia market. Ponatinib is key to Ariad's plans to transform itself from an innovative discovery and development enterprise to a global oncology business (scripintelligence.com, 5 June 2012).
You may also be interested in...
Lack Of Industry Involvement In EU HTA Scoping Process Exacerbates ‘Unworkable’ Timelines
Scientific advice could help companies make up for the lack of involvement in scoping, but slots are in short supply.
German HTA Queries Polivy Benefits Amid Lack Of Evidence
Roche’s lymphoma drug Polivy could face pricing challenges in Germany as it undergoes a full benefit assessment.
Germany Confirms No Reimbursement Status For ‘Lifestyle’ Drug Wegovy
In Germany Novo Nordisk’s obesity drug Wegovy will remain excluded from reimbursement for obesity, unlike Rhythm’s Imcivree.